For decades, Immunoglobulin G (IgG) has been the undisputed heavyweight champion of therapeutic monoclonal antibodies. From autoimmune diseases to oncology, IgG-based therapies dominate the biopharmaceutical market due to their long serum half-life, well-understood pharmacokinetics, and established manufacturing processes. However, when it comes to infectious diseases, relying solely on...